Epigenetic Strike Halts Cancer Genes in Aggressive Leukemia

Researchers at Monash University (with Harvard) found that targeting epigenetic proteins Menin and DOT1L can permanently switch off cancer-driving genes in certain leukemias, a finding that could enable shorter, less toxic therapies and is moving toward clinical trials later this year.